Raymond James & Associates Mirum Pharmaceuticals, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 137,628 shares of MIRM stock, worth $6.16 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
137,628
Previous 144,214
4.57%
Holding current value
$6.16 Million
Previous $4.93 Million
8.86%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding MIRM
# of Institutions
190Shares Held
54MCall Options Held
177KPut Options Held
167K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.57MShares$294 Million13.79% of portfolio
-
Janus Henderson Group PLC London, X04.48MShares$200 Million0.09% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.45MShares$154 Million2.37% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$145 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA3.08MShares$138 Million3.81% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $1.64B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...